Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced the publication of a peer-reviewed study in Biomedicines that demonstrates how its AI-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcinoma (HCC), the most common form of liver cancer. The study, published October 23, 2026, used Partitioned Literature Aggregation (PLA), Oncotelic's patented algorithm running on PDAOAI, alongside gene-expression and survival analyses to pinpoint four genes—FKBP1A, EIF4E, RRAGC and PPARGC1A—whose expression patterns are associated with patient survival. The signature was independently validated in a Japanese HCC cohort of 203 patients, lending credibility to the findings and suggesting the signature could serve as a reliable prognostic tool.
The implications of this announcement extend beyond a single cancer type. The ability to stratify patients based on a four-gene signature could improve the design of clinical trials for Sapu003, an intravenous formulation of everolimus that Oncotelic is developing. By identifying patients most likely to benefit, the company may be able to conduct more efficient trials and ultimately deliver more precise therapies. This aligns with a broader shift in oncology toward biomarker-driven drug development, where molecular signatures guide treatment decisions and increase the probability of success in clinical testing.
The research approach was presented by Oncotelic Chief Business Officer Saran Saund during an October 22 keynote at the 22nd Drug Discovery Strategic Summit in California. The company highlighted the potential of partitioned AI investigations to uncover testable biological hypotheses and accelerate drug discovery. Oncotelic plans to expand PDAOAI toward a target scale of approximately 100 billion biological vectors for genetic and protein research, a massive computational infrastructure that could enable researchers to interrogate complex biological systems at an unprecedented scale. Through its BIO REBOOT initiative, the company also invites researchers and development teams to submit projects for potential funding and support in validation, formulation, regulatory planning and clinical development, subject to scientific review and available resources.
The publication and the ongoing expansion of PDAOAI underscore Oncotelic's strategic bet on artificial intelligence as a core engine for drug discovery. If successful, the platform could reduce the time and cost associated with identifying novel drug targets and repurposing existing compounds. For investors, the peer-reviewed validation of the company's AI approach may bolster confidence in its pipeline and its ability to generate actionable insights from vast biological datasets. The full press release can be accessed at https://ibn.fm/ctJ4J, and the latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
BioMedWire, a specialized communications platform focused on biotechnology and life sciences, distributes this news as part of its offering. The platform is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and corporate communications solutions. For full terms of use and disclaimers, visit https://www.BioMedWire.com/Disclaimer.
